Estimated costs of false laboratory diagnoses of tuberculosis in three patients

Emerg Infect Dis. 2002 Nov;8(11):1264-70. doi: 10.3201/eid0811.020387.

Abstract

We estimated direct medical and nonmedical costs associated with a false diagnosis of tuberculosis (TB) caused by laboratory cross-contamination of Mycobacterium tuberculosis cultures in Massachusetts in 1998 and 1999. For three patients who received misdiagnoses of active TB disease on the basis of laboratory cross-contamination, the costs totaled U.S. dollars 32618. Of the total, 97% was attributed to the public sector (local and state health departments, public health hospital and laboratory, and county and state correctional facilities); 3% to the private sector (physicians, hospitals, and laboratories); and <1% to the patient. Hospitalizations and inpatient tests, procedures, and TB medications accounted for 69% of costs, and outpatient TB medications accounted for 18%. The average cost per patient was dollars 10873 (range, dollars 1033-dollars 21306). Reducing laboratory cross-contamination and quickly identifying patients with cross-contaminated cultures can prevent unnecessary and potentially dangerous treatment regimens and anguish for the patient and financial burden to the health-care system.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Antitubercular Agents / economics
  • Bacterial Typing Techniques
  • Contact Tracing / economics
  • Diagnostic Errors / economics*
  • Equipment Contamination
  • False Positive Reactions
  • Female
  • Health Care Costs*
  • Humans
  • Laboratories / economics*
  • Laboratories / standards
  • Male
  • Massachusetts
  • Middle Aged
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / isolation & purification
  • Specimen Handling
  • Tuberculosis / diagnosis*
  • Tuberculosis / drug therapy
  • Tuberculosis / economics*
  • Tuberculosis / microbiology

Substances

  • Antitubercular Agents